Skip to content

    India Pesticides

    IPL
    Chemicals·11 Aug 2025
    Management Summary

    India Pesticides Limited delivered a strong Q1 FY26, reporting significant revenue and profit growth driven by volume expansion and improved margins. The company successfully expanded its PEDA and formulation capacities, with further capacity additions on track. While facing minor headwinds from monsoon delays and pricing pressure in specific products, IPL remains optimistic about its growth trajectory, supported by strategic capex and a robust product pipeline.

    Highlights

    5
    • Revenue grew by 25.8% YoY to ₹282 crores, driven primarily by volume and sustained demand.

    • EBITDA increased by 62.6% YoY to ₹52 crores, with the EBITDA margin expanding by 4.17 percentage points to 18.4%.

    • Net profit surged by 79.2% YoY to ₹35 crores, and PAT margin expanded by 3.6 percentage points to 12.3%.

    • Return on Capital Employed (ROCE) improved significantly to 18.34% from 14%, reflecting better product mix and capital allocation.

    • Successful commissioning of expanded PEDA and formulation facilities, with PEDA capacity on track to reach 8,500 MTPA by Q2 FY26.

    Concerns

    3
    • Formulation sales were flat in Q1 FY26 (~₹78-80 crores) due to a slight delay in monsoon, though demand picked up in July.

    • Pricing pressure was observed in Prosulfocarb, although management stated it was offset by process optimization.

    • China competition remains a challenge, but management asserts competitiveness through optimized products and anti-dumping duties.

    What Changed2

    vs Q2 FY26

    Guidance items11 → 15 (+4)Risks discussed3 → 4 (+1)

    Key financials

    Single quarter

    14 metrics
    1. 01Revenue₹282 Cr+25.8%YoY
    2. 02EBITDA₹52 Cr+62.6%YoY
    3. 03EBITDA Margin18.4%
    4. 04PAT₹35 Cr+79.2%YoY
    5. 05PAT Margin12.3%

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    ₹116 crores

    primarily with internal accruals

    Debt

    Debt disclosed

    Liquidity

    Liquidity disclosed

    Company has a strong balance sheet with the ability to generate good free cash flow.

    Guidance & targets

    15
    CategoryTargetPriority
    Revenue
    Revenue Target
    ₹1,000 crores
    High
    Revenue
    Hamirpur Site Revenue
    ₹100 crores
    High
    Revenue
    Hamirpur Site Full Revenue Potential
    ₹1,000-1,100 crores
    Medium
    Profitability
    EBITDA Margin Target
    18%-20%
    High
    Profitability
    EBITDA Margin
    18% to 20%
    High
    Capacity
    PEDA Capacity Expansion
    8,500 metric tons per annum
    High
    Capacity
    PEDA Capacity Ready
    8,500 tons
    High
    Capacity Utilization
    Overall Capacity Utilization
    >70%
    High
    Sales
    PEDA + Pretilachlor Sales
    ₹150 crores
    High
    Sales
    PEDA + Pretilachlor Sales
    ₹250-300 crores
    Medium
    Revenue Growth
    Revenue Growth
    15% to 20%
    High
    Product Launches
    New Product Launches
    5 products (2 in IPL, 3 in Shalvis)
    High
    Capital Investment
    Hamirpur Site Total Investment
    ₹400-500 crores
    Medium
    Sales Mix
    H1 Turnover Ratio
    55%-56%
    High
    Sales Mix
    H2 Turnover Ratio
    43%-44%
    High

    PEDA Capacity Expansion Completion

    Q2 FY26 (by September-October)
    Current6,000 tons per annum, further augmentation in progress
    Target8,500 metric tons per annum capacity fully operational

    Why it matters

    This expansion is crucial for meeting substantial Indian demand and driving overall volume growth.

    Looking ahead, the company is on track to expand capacity to 8,500 metric tons per annum by Q2 FY 26

    How to verify

    guidance_and_targets[metric='PEDA Capacity Expansion']

    Risks & concerns

    4
    RiskSeverity

    US Tariffs on Exports

    US tariffs are not substantial as they are similar for India and China, affecting only 3-4% of turnover in niche products.Analyst downplayed

    low

    Pricing Pressure on Prosulfocarb

    Some pricing pressure exists on Prosulfocarb, but the company has optimized its process to nullify the price decrease.Analyst acknowledged

    medium

    Competition from China

    China is a constant challenge, but IPL is competitive due to optimized products and benefits from anti-dumping duties on products like Pretilachlor.Both acknowledged

    medium

    Monsoon Delay Impact on Formulation Sales

    A slight delay in monsoon (starting mid-July) affected Q1 FY26 formulation sales, but demand picked up substantially in July, with growth expected in Q2.Analyst acknowledged

    low

    Q&A highlights

    8

    “The revenue target what we have fixed is Rs. 1,000 crores for FY25-26 with a margin between 18%-20%.”

    Management provided clear numerical guidance for the full fiscal year's top-line and profitability.

    asked by Ankit from Adezi Ventures Family Office

    3 min read7 chapters

    Detailed Narrative

    01

    Robust Q1 FY26 Financial Performance

    India Pesticides Limited reported a strong Q1 FY26, with revenue reaching ₹282 crores, marking a 25.8% year-on-year and 34% quarter-on-quarter growth. This was primarily volume-led, supported by sustained demand in both domestic and international markets. EBITDA increased by 62.6% YoY to ₹52 crores, resulting in an EBITDA margin of 18.4%, an expansion of 4.17 percentage points. Net profit stood at ₹35 crores, growing 79.2% YoY, with a PAT margin of 12.3%, up 3.6 percentage points.

    02

    Strategic Capacity Expansion and Utilization

    The company successfully commissioned an expanded intermediate PEDA facility, increasing its capacity from 2,000 tons to 6,000 tons per annum, with a further scale-up to 8,500 metric tons per annum expected by Q2 FY26. Additionally, formulation capacity was augmented by 3,500 MT per annum. Overall blended capacity utilization was approximately 80%, with technical capacity at 73% and formulation capacity fully utilized, demonstrating efficient asset deployment.

    03

    FY26-27 Growth Outlook and Targets

    IPL has set a revenue target of ₹1,000 crores for FY26, aiming for an EBITDA margin between 18-20%. For FY27, the company envisages a revenue growth of 15-20% while maintaining EBITDA margins in the 18-20% range. Sales of PEDA and Pretilachlor are projected to reach ~₹150 crores in FY26 and ₹250-300 crores in FY27, driven by increased capacity and market demand. The company also plans to launch two new products in IPL and three in its subsidiary Shalvis next year.

    04

    Hamirpur Greenfield Project as a Long-Term Driver

    A significant capital expenditure of ₹64 crores is planned for the Hamirpur site in FY26, part of the total ₹116 crores capex for the year. This greenfield project is expected to generate approximately ₹100 crores in revenue in FY26-27. Over the long term, the Hamirpur site has a revenue potential of ₹1,000-1,100 crores within 3-4 years, requiring a total investment of ₹400-500 crores, which will be primarily funded through internal accruals.

    05

    Product Mix and Market Dynamics

    The company experienced robust growth in its herbicide business, with Pretilachlor sales reaching ~₹55 crores in Q1 FY26, benefiting from anti-dumping duties that normalized prices. Demand for fungicides like Captan and Folpet is increasing, with Folpet seeing strong export demand. While Prosulfocarb faced some pricing pressure, process optimization helped mitigate the impact. Formulation sales were flat in Q1 due to a delayed monsoon but showed substantial growth in July, indicating a recovery.

    06

    Backward Integration and Competitive Stance

    IPL's strategy emphasizes backward integration, with all major existing products, including Pretilachlor, Captan, and Folpet, being backward integrated. For new products, the company adopts a phased approach, starting with introduction and then pursuing backward integration based on market response. Management acknowledged China as a competitive challenge but asserted that IPL is well-positioned due to optimized products, competitive pricing, and the benefit of anti-dumping duties on key molecules.

    07

    Improved ROCE and Financial Prudence

    The company's Return on Capital Employed (ROCE) significantly improved to 18.34% from 14%, a direct outcome of a better product mix and efficient capital allocation. Management expects interest costs to reduce in subsequent quarters of FY26, driven by the liquidation of herbicide inventory and lower working capital limits. This disciplined approach underscores the company's commitment to sustainable, profitable growth and efficient financial management.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.